Abstract
Objective: Roquinimex is a drug with effects on inflammation and tumors. The pharmacological effect is not fully understood, and the molecular mechanism most characterized in vitro is an increase of plasminogen activator inhibitor type 2 (PAI-2) in human peripheral blood monocytes. The aims were to investigate peripheral pharmacological effects of roquinimex on peripheral blood monocytes and dog gingival fluid (GCF).___TAGSTART___BR___TAGEND___ Design: Six dogs were used in a cross-over study. The amount of GCF was determined with a Periotron®. The PAI-2 concentration in GCF was determined with ELISA. Monocytes were isolated from peripheral blood.___TAGSTART___BR___TAGEND___ Results: Dogs treated with the drug had significantly lower GCF flow values and the PAI-2 concentration in GCF was higher, but no effect was seen on peripheral monocytes.___TAGSTART___BR___TAGEND___ Conclusion: Roquinimex treatment led to a consistently decreased flow rate of GCF and a higher local concentration of PAI-2 in GCF.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Attström, R. (1975). The roles of gingival epitheliumand phagocyting leukocytes in gingival defence, J. Clin. Periodontol. 2, 25–32.
Billström, A., Kinnby, B., Lecander, I., et al. (1996). Production of plasminogen activator inhibitor type-2 in human peripheral blood monocytes upregulated in vitro by the quinoline-3-carboxamide, Linomide, Fibrinolysis 10, 277–283.
Billström, A. (1997). The significance of urokinase-type plasminogen activator (u-PA) in tumour growth and Linomide-induced upregulation of u-PA's endogenous inhibitor PAI-2, Thesis, Lund University, Sweden.
Birkedal-Hansen, H. (1993). Role of matrix metalloproteinases in human periodontal diseases, J. Periodontol. 64 (Suppl. 5), 474–484.
Birkedal-Hansen, H. (1995). Matrix metalloproteinases, Adv. Dent. Res. 9 (Suppl. 3), 16.
Brodsky, S. V. (2002). Coagulation, fibrinolysis and angiogenesis: New insights from knock-out mice, Exp. Nephrol. 10, 299–306.
Danø, K., Rømer, J., Nielsen, B. S., et al. (1999). Cancer invasion and tissue remodeling-cooperation of protease systems and cell types, APMIS 107, 120–127.
Deinzer, R., Mossanen, B. S. and Herforth, A. (2000). Methodological considerations in the assessment of gingival crevicular fluid volume, J. Clin. Periodontol. 27, 481–488.
Egelberg, J. (1964). Gingival exsudate, Odontol. Rev. 15, 381–398.
Electricwala, A. and Atkinson, T. (1985). Purification and properties of plasminogen activators from epithelial cells, Eur. J. Biochem. 147, 511–516.
Groisman, M. and Klinge, B. (1990). Clinical and histological findings in ligature-induced experi-mental periodontitis in dogs. A pilot study, J. Clin. Periodontol. 17, 86–90.
Hart, P. H., Vitti, G. F., Burgess, D. R., et al. (1989). Human monocytes can produce tissue-type plasminogen activator, J. Exp. Med. 169, 1509–1514.
Karussis, D. M., Lehmann, D., Slavin, S., et al. (1993). Treatment of chronic-relapsing experi-mental autoimmune encephalomyelitis with the syntetic immunmodulator linomide (quinoline-3-carboxamid), Proc. Natl. Acad. Sci. USA 90, 6400–6404.
Karussis, D. M., Lehmann, D., Brenner, T., et al. (1994). Immunomodulation of experimental autoimmune myasthenia gravis with linomide, J. Neuroimmunol. 55, 187–193.
Karussis, D. M., Meiner, Z., Lehmann, D., et al. (1996). Treatment of secondary progressive multiple sclerosis with the immunmodulator linomide, Neurology 47, 341–346.
Kinnby, B., Matsson, L. and Lecander, I. (1994). The plasminogen-activatingsystem in gingival fluid fromadults. An intra-individual study before and after treatment of gingivitis, Scand. J. Dent. Res. 102, 334–341.
Kinnby, B. (2002). The plasminogen activating system in periodontal health and disease, Biol. Chem. 383, 85–92.
Kruithof, E. K. O., Baker, M. S. and Brunn, C. L. (1995). Biogical and clinical aspects of plasminogen activator inhibitor type 2, Blood 86, 4007–4024.
Lecander, I. and Åstedt, B. (1987). Specific plasminogen activator inhibitor of placental type, PAI-2 occurring in amniotic fluid and cord blood, J. Clin. Lab. Clin. Med. 110, 602–605.
Lindhe, J., Hamp, S. E. and Löe, H. (1973). Experimental gingivitis in the Beagle dog, J. Periodont. Res. 8, 1–10.
Lindberg, P., Kinnby, B., Lecander, I., et al. (2000). Description of the plasminogen activating system in canine gingival crevicular fluid, Fibrinolysis Proteolysis 14, 337–342.
Lindberg, P., Kinnby, B., Lecander, I., et al. (2001). Increasing expression of tissue plasminogen activator and plasminogen activator inhibitor type 2 in dog gingival tissue with progressive inflammation, Arch. Oral Biol. 46, 23–31.
Matrisian, L. M. (1992). The matrix-degradingmetalloproteinases, Bioessays 14, 455–463.
Matsson, L. (1978). Development of gingivitis in pre-school children and young adults. A comparative experimental study, J. Clin. Periodontol. 5, 24–34.
Matsson, L. and Attström, R. (1979). Development of experimental gingivitis in the juvenile and adult beagle dog, J. Clin. Periodontol. 6, 186–193.
Nagler, A., Feferman, R. and Shoshan, S. (1997). Reduction in basic fibroblast growth factor mediated angiogenesis in vivo by linomide, Connect. Tissue Res. 37, 61–68.
Parenti, A., Donnini, S., Morbidelli, L., et al. (1996). The effect of linomide on the migration and the proliferation of capillary endothelial cells elicited by vascular endothelial growth factor, Br. J. Pharmacol. 119, 619–621.
Rijken, D. C. (1995). Plasminogen activators and plasminogen activator inhibitors: biochemical aspects, Bailliere Clin. Haematol. 8, 291–312.
Schroeder, H. E. and Listgarten, M. A. (1997). The gingival tissues: the architecture of periodontal protection, Periodontology 13, 91–120.
Schuler, E., Romisch, J., Paques, E.-P., et al. (1993). The use of inhibitors of plasminogen activators for the treatment of inflammation and wounds, European Patent No. 567816.
van Hinsbergh, V. W., Kooistra, T., Emeis, J. J., et al. (1991). Regulation of plasminogen activator production by endothelial cells: role in fibrinolysis and local proteolysis, Int. J. Radiat. Biol. 60, 261–272.
Vukanovic, J. and Isaaks, J. T. (1995). Linomide inhibits angiogenesis, growth, metastasis and macrophage infiltration within rat prostatic cancers, Cancer Res. 55, 1499–1504.
Werb, Z., Mainardi, C. L., Vater, C. A., et al. (1977). Endogenous activiation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator, N. Engl. J. Med. 296, 1017–1023.
Wohlwend, A., Belin, A. and Vassalli, J. D. (1987). Plasminogen activator-specific inhibitors produced by human monocytes/ macrophages, J. Exp. Med. 165, 320–339.
Yin, X., Bunn, C. L. and Bartold, P. M. (2000). Detection of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 2 (PAI-2) in gingival crevicular fluid from healthy, gingivitis and periodontal patients, J. Clin. Periodontol. 27, 149–156.
Ziche, M., Gasparini, G., Choudhuri, R., et al. (1997). Antiangiogenic effect of Linomide on breast cancer VEGF transfectants, Oncol. Rep. 4, 253–256.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lindberg, P., Billström, A. & Kinnby, B. Reduced gingival fluid flow: a peripheral marker of the pharmacological effect of roquinimex. Inflammopharmacology 11, 267–276 (2003). https://doi.org/10.1163/156856003322315613
Issue Date:
DOI: https://doi.org/10.1163/156856003322315613